Merck pushes small batch of price hikes, including top-selling Keytruda and Gardasil

Merck raised the price of Keytruda by 1.5% and Gardasil by 6%, according to a spokeswoman. (Merck)

After Pfizer came under presidential fire for price hikes this summer, Merck & Co. promised to pump the brakes on its own increases. Now, it’s pushing up stickers on a handful of therapies—including a couple of top sellers—but maintains that it’s still keeping its word.

The company raised prices for its top-sellers Keytruda to treat cancer and HPV vaccine Gardasil by 1.5% and 6%, respectively. Three other vaccines received price hikes. Keytruda has already generated $5 billion in sales this year, while Gardasil has pulled in more than $2.3 billion as of Merck's third-quarter results.

A Merck spokeswoman said the moves are "fully consistent with Merck’s commitment to not increase net price across our product portfolio in the U.S. by more than inflation annually."

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

She added that Merck "remains committed to responsibly pricing our medicines, as our company always has been."

The moves follow Merck’s commitment in July to not raise average net prices by more than the rate of inflation. At the time, Credit Suisse analyst Vamil Divan wrote that it’s not much of a strategy change “as we do not believe they have been getting much more than this level of net pricing in recent years anyway.”

Last year, Merck's average net prices actually declined, according to the company's spokeswoman.

RELATED: Merck’s price cuts are flashy, but no more benevolent than Pfizer’s freeze: analysts

In its July pricing commitment, Merck also said it would reduce certain prices, such as a 60% slash to its list price for hepatitis C drug Zepatier. After a closer look, one analyst pointed out that Zepatier has struggled against competition and doesn’t generate significant sales for the company. Additionally, Merck pledged price reductions for six other “tiny” drugs by sales, Evercore ISI analyst Umer Raffat wrote at the time.

Merck’s latest move to raise list prices comes as Pfizer gets ready to implement 41 of its own increases early next year. That drugmaker came under scrutiny from Trump this summer when it moved to raise dozens of prices. Trump tweeted that Pfizer “should be ashamed” and the company ended up deferring its hikes.

RELATED: Pfizer, plotting 41 price hikes for January, returns to 'business as normal' after price-raising pause

On a recent conference call, CEO Ian Read said the company would likely be ready to return to “business as normal” on pricing in January; this month, the company laid out its plan for the increases. Pfizer plans list price increases of 5% on 37 drugs, plus a 9% hike for one med and 3% increases on three drugs. Together, the 41 drugs getting price hikes represent about a tenth of the company’s portfolio.

Amid Pfizer’s pricing firestorm this summer, Novartis and Roche also pledged to hold off price hikes this year.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.